Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

HYDERABAD: India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of ...

Handelsbanken Fonder AB raised its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 15.4% in the fourth quarter, according to the company in its most recent disclosure ...

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data reado ...

A global elderly and aging population has significant impacts, not only in terms of individual health risk but in terms of ...

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

Prothena (NASDAQ:PRTA – Free Report) had its target price upped by Piper Sandler from $94.00 to $110.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

A 24-year-old woman from York has become one of the first patients in the world to take part in a pioneering research study ...

Xenon Pharmaceuticals XENE reported a loss of 84 cents per share for the fourth quarter of 2024, narrower than the Zacks ...

RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored ...